Clin Exp Vaccine Res.  2019 Jan;8(1):1-3. 10.7774/cevr.2019.8.1.1.

A national project to build a business support facility for plant-derived vaccine

• Choi BH
• Kim DY

• KMID: 2438955
• DOI: http://doi.org/10.7774/cevr.2019.8.1.1

Abstract

No abstract available.

MeSH Terms

Commerce*

Figure

• 

  Fig. 1 Plant-derived vaccine facility.

• 

  Fig. 2 Plant (Nicotiana benthamiana) breeding facility.

Reference

1. Obembe OO, Popoola JO, Leelavathi S, Reddy SV. Advances in plant molecular farming. Biotechnol Adv. 2011; 29:210–222.

2. Buyel JF. Process development strategies in plant molecular farming. Curr Pharm Biotechnol. 2015; 16:966–982.

3. Takeyama N, Kiyono H, Yuki Y. Plant-based vaccines for animals and humans: recent advances in technology and clinical trials. Ther Adv Vaccines. 2015; 3:139–154.

4. Floss DM, Falkenburg D, Conrad U. Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants: an overview. Transgenic Res. 2007; 16:315–332.

5. Maxmen A. Drug-making plant blooms. Nature. 2012; 485:160.

6. Bixler SL, Duplantier AJ, Bavari S. Discovering drugs for the treatment of Ebola virus. Curr Treat Options Infect Dis. 2017; 9:299–317.

7. Tschofen M, Knopp D, Hood E, Stoger E. Plant molecular farming: much more than medicines. Annu Rev Anal Chem (Palo Alto Calif). 2016; 9:271–294.

8. Xu J, Dolan MC, Medrano G, Cramer CL, Weathers PJ. Green factory: plants as bioproduction platforms for recombinant proteins. Biotechnol Adv. 2012; 30:1171–1184.

9. Yusibov V, Streatfield SJ, Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum Vaccin. 2011; 7:313–321.

10. Sack M, Hofbauer A, Fischer R, Stoger E. The increasing value of plant-made proteins. Curr Opin Biotechnol. 2015; 32:163–170.